CRDL vs. ATXS, AURA, PHAT, CMRX, ORKA, ATAI, RVNC, PRME, ESPR, and RGNX
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Astria Therapeutics (ATXS), Aura Biosciences (AURA), Phathom Pharmaceuticals (PHAT), Chimerix (CMRX), Oruka Therapeutics (ORKA), Atai Life Sciences (ATAI), Revance Therapeutics (RVNC), Prime Medicine (PRME), Esperion Therapeutics (ESPR), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs.
Astria Therapeutics (NASDAQ:ATXS) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
In the previous week, Cardiol Therapeutics had 2 more articles in the media than Astria Therapeutics. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Astria Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.88 beat Astria Therapeutics' score of 0.37 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.
99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 2.9% of Astria Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Astria Therapeutics currently has a consensus price target of $25.67, indicating a potential upside of 275.24%. Cardiol Therapeutics has a consensus price target of $8.40, indicating a potential upside of 591.36%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Astria Therapeutics.
Astria Therapeutics received 543 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 73.04% of users gave Astria Therapeutics an outperform vote while only 65.00% of users gave Cardiol Therapeutics an outperform vote.
Astria Therapeutics' return on equity of -43.58% beat Cardiol Therapeutics' return on equity.
Astria Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.
Astria Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Summary
Cardiol Therapeutics beats Astria Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRDL) was last updated on 2/21/2025 by MarketBeat.com Staff
Free CRDL Stock Alerts